Artikel
Is the distance between patient's residency and the speciality clinic a predictor for overall survival of Glioblastoma patients?
Beeinflusst die Distanz zwischen Wohnort und neuroonkologischem Zentrum das Gesamtüberleben von Patienten mit Glioblastomen?
Suche in Medline nach
Autoren
-
Marcel A. Kamp
- Universitätsklinikum Jena, Zentrum für Neuroonkologie, Klinik für Neurochirurgie, Jena, Deutschland; Universitätsklinikum Jena, Klinik und Poliklinik für Neurochirurgie, Jena, Deutschland
-
Annett Bartholdt
- Universitätsklinikum Jena, Zentrum für Neuroonkologie, Klinik für Neurochirurgie, Jena, Deutschland; Clinical Cancer Registry Thuringia, Jena, Deutschland
-
Nazife Dinc
- Universitätsklinikum Jena, Klinik und Poliklinik für Neurochirurgie, Jena, Deutschland
-
Christiane von Sass
- Universitätsklinikum Jena, Klinik und Poliklinik für Neurochirurgie, Jena, Deutschland
-
Thomas Ernst
- Universitätsklinikum Jena, Zentrum für Neuroonkologie, Klinik für Neurochirurgie, Jena, Deutschland; Clinical Cancer Registry Thuringia, Jena, Deutschland; Universitätsklinikum Jena, Department of Haematology and Medical Oncology, Jena, Deutschland
-
Christian A. Senft
- Universitätsklinikum Jena, Klinik und Poliklinik für Neurochirurgie, Jena, Deutschland; Universitätsklinikum Jena, Zentrum für Neuroonkologie, Jena, Deutschland
| Veröffentlicht: | 25. Mai 2022 |
|---|
Gliederung
Text
Objective: Glioblastomas are the most malignant astrocytoma with a significantly limited prognosis. Numerous prognostic markers, such as IDH mutation, MGMT promoter hypermethylation, general condition, and the form of operative and adjuvant therapy, were identified. There are also numerous additional factors that presumably influence the prognosis, but their significance has not yet been investigated in controlled studies.
It is well-known from several neurosurgical emergencies that the distance between the place of residence and the tertiary care centre influences the prognosis. The aim of the present epidemiological pilot series was to investigate whether the distance between the place of residence and the neuro-oncological centre influences the overall survival.
Methods: The data for this analysis were obtained from the local cancer registry. Inclusion criteria were (1) inclusion in the local cancer registry, (2) diagnosis of glioblastoma, (3) initial diagnosis between 01/2007 and 12/2017. The distance between clinic and residency as a straight line, travel by car and the time required were determined using google maps. Overall survival is calculated from the date of diagnosis and the death dates from the registry offices. Data were collected and analysed using the Prism 9 programme (GraphPad Prism).
Results: 232 fulfilled the inclusion criteria and suffered from glioblastoma. 100 patients were female, 132 males. Median age was 62 years (22 – 81 years). 194 patients were treated by tumour resection, 33 were diagnosed by stereotactic biopsy and 5 patients no kind of surgery. All except 7 patients were treated by radiation therapy (median radiation dose 60 Gy, 10-66 Gy) and all patients received temozolomide chemotherapy as first-line chemotherapy. The overall survival in this historic cohort was 11 month (0–101 month).
The median distance between the neurooncological department and patient’s residency as a straight line was 23.4 km (0,5 – 346 km), the median distance required for traveling by car was 35.7 km (1.2 – 494 km) and the median time required for the distance between patient´s home and the clinic was 32 min (3 – 305 min). None of the distance parameter correlated with the overall survival in the linear regression analysis (each p > 0.8).
Conclusion: In contrast to other neurosurgical emergencies, distance between patient´s home and the speciality clinic is not a predictor for overall survival.
